DEA CME

The DEA now requires all DEA-registered practitioners to complete a one-time, eight-hour training requirement on the treatment and management of patients with opioid or other substance use disorders. Your deadline is the date of your next scheduled DEA registration submission on or after June 27, 2023. This course, developed and Accredited by AffinityCE, an ACCME Accredited and DEA-Qualified Provider, in partnership with PRESENT e-Learning Systems, fulfills that requirement. The course is presented in 8 easy to digest modules. You can complete them on your own time schedule. You will receive a Certificate of Completion for each of the 8 modules which is your evidence of having completed the requirement. This course also includes 8 hours of CME credit for MD, DO, DPM, PA, NPs. Others will receive a certificate of completion. You will receive a separate CME/Completion certificate IN ADDITION to your DEA Certificate of Completion for each module you complete.

When you attend the DEA Required Substance Use Disorders Training, you will obtain 8 CECH/CME credit that you can apply toward your state requirement. This course is developed and accredited by AffinityCE, an ACCME accredited and DEA-qualified provider. PRESENT e-Learning Systems is approved by the Council on Podiatric Medical Education as a provider of continuing education in podiatric medicine, and has approved this activity for 8 continuing medical education contact hours.

Pri-Med is committed to supporting you in meeting the Drug Enforcement Administration (DEA) CME training requirements under the MATE Act. The free CME courses offered here focus on opioid and substance use disorders and can be combined in any way to complete the eight-hour training mandate. 

This course provides 2 AMA PRA Category 1 Credit for license renewal and talks about the pharmacology, adverse effects, dosage, and administration of FDA-approved treatments for acute pain like nonopioid analgesics, adjuvant pain medications, migraine medicines, Tramadol/Celecoxib (Seglentis), Bupivacaine/Meloxicam (Zynrelef), IV Meloxicam (Anjeso), and Benzhydrocodone/Acetaminophen (Apadaz).

Activity Description / Statement of Need:

In this online, self-learning activity:

Dry eye disease (DED) is a condition with a diverse group of etiologies and whose common symptoms include discomfort or pain, visual disturbance, tear film instability, and ocular surface inflammation. Compared with those without the condition, patients with DED experience higher rates of loss of work productivity, impaired of daily activities, medical visits, and sleep and mood disorders, and worse emotion well-being and overall quality of life. Although the prevalence of DED varies based on a variety of patient factors, estimates place it as high as 20% of the adult population and more than 34% in the elderly. The aggregate U.S. economic impact is estimated be over $3 billion in direct medical expenses and $55 billion in indirect expenses annually. Nonetheless, DED is both underdiagnosed and undertreated.

Target Audience:

The following HCPs: ophthalmology and optometry; physician assistants and nurse practitioners who practice or are interested in ophthalmology; and any other healthcare professionals with an interest in or who clinically encounter patients with dry eye.